ILSI-Biomed Israel

Start-up Weekly: MGVS – a Israeli Cell / Gene Therapy Company

MGVS is a promising Israeli company, whose leading product has passed Phase I/II trial in December 2009 and could be used to treat critical limb ischemia. PLUS they're currently recruiting! Name: MGVS Ltd. CEO: Guy Yachin Sector: Biotechnology Suc-Sector: Cell therapy Medical Field: Cardiovascular Est.: 2000 Stage: Phase I/IIa Clinical trials Vision: To become the leader in advanced cell therapy based solutions for cardiovascular patients Employees: 21 and currentl...

Almost-Breakthroughs of the Year: Genetic Engineering and Longevity Drug

The magazine Science picked two runner-ups for the Breakthrough of the Year award: genetic engineering and a novel longevity drug Do you read Science, the magazine? You really should. It's one of the best sources for breakthroughs in research. This month they have a special section, where they tried to pick the Breakthrough of the Year. They probably had to do quite a lot of thinking, but eventually they settles on the discovery of Ardi - the missing link between our ancient ape-like ance...

A Single Shot of Genetically Engineered Viruses Cured Legal Blindness

In a phase I clinical trial, researchers used gene therapy to cure a genetic disorder causing legal blindness Those of us dealing in the field of biomed are probably tired of hearing people ask about genetic engineering, and when-oh-when will we be able to cure all the illnesses of the world with it. While genetic engineering does have plenty of potential for treatment of genetic disorders, most of the scientific research in the field screeched to a halt eight years ago, when certain genetica...